Enlivex Ltd. has taken a significant step to strengthen its financial position by announcing a $7.5 million registered direct offering. This offering includes ordinary shares and warrants, designed to support the company's ongoing clinical programs and operational needs.

The announcement, made on November 16, 2026, comes as part of a securities purchase agreement entered into with certain investors. The offering is priced at $1.315 per share, which represents a premium over the closing price on November 13, 2026. The funds raised are expected to be used for various purposes, including clinical and regulatory activities, manufacturing, research and development, and potential acquisitions.

Background

Enlivex Ltd., classified under the SIC code 6199 for Finance Services, operates primarily in the financial sector. The company is listed on the Nasdaq under the ticker symbol ENLV. Recent filings indicate that Enlivex has been active in securing funding to support its innovative approaches to longevity and health.

What the Filing Says

The filing details that the registered direct offering will be executed in a series of closings, with the initial closing expected around November 17, 2026. Investors will initially purchase $500,000 worth of securities, followed by additional monthly closings totaling $7 million over the next ten months. The offering is structured to allow payments in U.S. dollars or Tether (USDT).

Impact

This offering may impact various stakeholders, including current shareholders and potential investors. The structure of the offering, which includes pre-funded warrants and ordinary warrants, allows for flexibility in how investors can engage with the company. Additionally, the expected use of proceeds for clinical advancements could enhance the company’s market position.

What's Next

The initial closing of the offering is anticipated to occur shortly, subject to customary closing conditions. However, certain subsequent closings may be postponed pending shareholder approval for an increase in authorized share capital.